Compare MTRX & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTRX | ELDN |
|---|---|---|
| Founded | 1984 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.0M | 291.8M |
| IPO Year | 1995 | 2014 |
| Metric | MTRX | ELDN |
|---|---|---|
| Price | $10.84 | $3.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $17.00 | $8.50 |
| AVG Volume (30 Days) | 188.2K | ★ 872.7K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $769,286,000.00 | N/A |
| Revenue This Year | $19.75 | N/A |
| Revenue Next Year | $7.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.64 | N/A |
| 52 Week Low | $9.88 | $1.35 |
| 52 Week High | $15.97 | $4.60 |
| Indicator | MTRX | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 36.92 | 35.97 |
| Support Level | $10.79 | $2.68 |
| Resistance Level | $12.48 | $4.21 |
| Average True Range (ATR) | 0.30 | 0.16 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 17.75 | 4.13 |
Matrix Service Co provides engineering, fabrication, construction, maintenance, and repair services prominently to the energy and industrial markets. The company operates through three main segments: Storage and Terminal Solutions, Utility and Power Infrastructure, and Process and Industrial Facilities. These segments cover services like building and maintaining storage tanks and terminals, supporting power delivery and new power generation projects including renewables, as well as plant maintenance and turnarounds for refining and petrochemical industries. Matrix generates revenue by delivering these services to clients in oil, gas, power, and petrochemical sectors across North America and internationally.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.